Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

------------------------- --------------------------------------- Basic and diluted net loss per common share $ (0.14) $ (0.02) --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- Weighted average shares outstanding (000's) - basic & diluted 85,122 85,122 --------------------------------- --------------------------------------- --------------------------------- --------------------------------------- (in thousands of U.S.$, except Three months ended share and per share data) June 30, 2008 ------------------------------------------------------------------------- Reported Adjustments Adjusted REVENUE Royalty revenue $ 25,536 $ - $ 25,536 Product sales, net 50,533 - 50,533 License fees 53 (53) a - --------------------------------- --------------------------------------- 76,122 (53) 76,069 --------------------------------- --------------------------------------- EXPENSES License and royalty fees 3,661 - 3,661 Cost of products sold 26,809 (28) b 26,781 Research and development 18,584 (1,366) c 17,218 Selling, general and administrative 25,813 (2,167) d 23,646 Depreciation and amortization 8,539 (7,593) e 946 --------------------------------- --------------------------------------- 83,406 (11,154) 72,252
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 RXi Pharmaceuticals ... company focused on discovering, developing and commercializing innovative ... technologies, today announced that it has been granted a ... Office on its unique delivery system for delivering ... phagocytic cells for the treatment of diseases with ...
(Date:9/17/2014)... 17, 2014 First ... from a truly novel class of anti-infective ... Biopharma, a biopharmaceutical company developing a truly ... it has secured £4.0m ($6.4m) to advance ... against a range of Gram-positive infections including  ...
(Date:9/16/2014)... “Nature has developed, very cleverly, some lessons ... in optical design,” said Joseph Shaw, director of the ... explore surfaces and structures at the nanoscale, we’ll discover ... San Diego in August during a conference called “ ... by Shaw and Rongguang Liang of the University of ...
(Date:9/16/2014)... WASHINGTON, D.C., September 16, 2014 --The emerging field ... portable to the next level, enabling the construction ... highly efficient devices, individual molecules would take on ... and transistors. , A team of researchers from ... potential candidate for use in small-scale electronics: a ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2
... Champions Oncology Inc. (OTC: CSBR) announced today that ... certification from the Maryland Department of Health and Mental ... company to conduct medical laboratory tests. ... approval is a significant milestone for our Company. This ...
... 2012 The " Anesthesia Drugs Market ... analyzes and studies the U.S. market for intravenous anesthesia drugs with special ... export & import system for controlled substances in U.S. and U.S. market ... TOC of   " Anesthesia Drugs Market ...
... was able to reach for and sip from a drink on ... by using her thoughts to direct a robotic arm. ... is evaluating the safety and feasibility of an investigational device called ... brain-computer interface (BCI) intended to put robotics and other assistive technology ...
Cached Biology Technology:Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 2Champions Oncology Inc. Receives Approval from U.S. Regulatory Authorities 3Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 2Anesthesia Drugs Market in U.S. worth $7 Billion by 2015: MarketsandMarkets 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 2Paralyzed individuals use thought-controlled robotic arm to reach and grasp 3Paralyzed individuals use thought-controlled robotic arm to reach and grasp 4Paralyzed individuals use thought-controlled robotic arm to reach and grasp 5
(Date:9/16/2014)... same viruses that make us sick can take up ... a sneeze, cough or other troublesome symptom, according to ... St. Louis. , On average, healthy individuals carry ... researchers report online in BioMed Central Biology . ... the diversity of viruses in healthy people. , ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
(Date:9/16/2014)... new school year, a new football season and another ... September, SpaceX,s Dragon spacecraft is scheduled to blast off ... part of the company,s fourth contracted mission to the ... third suite of research investigations sponsored by the Center ... the role of managing the U.S. National Laboratory on ...
Breaking Biology News(10 mins):Healthy humans make nice homes for viruses 2Healthy humans make nice homes for viruses 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4CASIS research set for launch aboard SpaceX mission to space station 2CASIS research set for launch aboard SpaceX mission to space station 3
... Conn.A team led by Yale University researchers has used ... the first time. Their findings, which appear December 13 ... , could dramatically simplify the way physicians test for ... The teamled by Mark Reed, Yale,s Harold Hodgkinson Professor ...
... fruit increases, growers are being challenged to bring ... their bottom line, orchard owners are experimenting with ... reducing labor costs. Hand thinning, a common ... fruit, is among the most labor-intensive of orchard ...
... degrade the diverse types of defective proteins and thus protect ... Professor Thomas Sommer, Professor Udo Heinemann and Dr. Ernst Jarosch ... Germany, have now found a crucial piece in this puzzle. ... the quality control of proteins, they discovered a scaffold regulating ...
Cached Biology News:Scientists use nanosensors for first time to measure cancer biomarkers in blood 2Horizontal string trimmer reduces labor costs, increases peach size 2MDC researchers identify a scaffold regulating protein disposal 2
... is a personal desktop unit ideal for use ... , Rotation speed set at 12 rpm ... C , Bottle capacity of four 35 ... ml conical ,plastic bottles , Consistent, repeatable ...
... The SC250 Express is the latest edition ... SC250 Express has an extra large diameter ... The digital display panel allows precise setting ... Large chamber for handling large quantities and ...
... a no-frills, basic SpeedVac concentrator designed for ... this unit still features a standard Teflon ... of time and heat. It is designed ... a wide variety of different rotors for ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: